Dealing with NASH “mildly abnormal LFTs”. Liver disease is a national epidemic.

Slides:

Advertisements

Similar presentations

Evaluation of Abnormal Liver Function Tests Dr Deb Datta Consultant Gastroenterolgist.

Advertisements

Diabetes Mellitus and Non- Alcoholic Fatty Liver Diseas

Alfredo ALBERTI. How to predict outcome in hepatitis C patients Alfredo Alberti Department of Clinical and Experimental Medicine Venetian Institute of.

Update in Liver Disease SGNA April 4, 2014 Outline Interpretation of elevated liver chemistries Fatty liver disease Hepatitis B Hepatitis C.

Non-alcoholic fatty liver disease and when to refer abnormal LFTs

NONALCOHOLIC FATTY LIVER DISEASE

Predictors of elevated transaminase levels in patients with central obesity V. Papastergiou, G. Ntetskas, L. Skorda, F. Lambrianou, K. Roufas, E. Asonitis,

Clinical Biochemistry For GPs

Liver Function Tests (LFTs)

V.E.I.L. Liver Cancer Prevention. 1. Vaccination Birth dose + 2 Universal for those not already chronics Screening pregnant women Catch up vaccination.

 Primary liver cancer is the fifth most common cancer in the world and the third most common cause of cancer mortality  Hepatocellular carcinomas (HCCs)

Liver Cirrhosis S. Diana Garcia

National Hepatitis C Database Dr Lelia Thornton Health Protection Surveillance Centre December 2012.

Hepatitis C for the General Practitioner Morris Sherman MB BCh PhD FRCP(C) University of Toronto January 2013.

WORKSHOP B ALCOHOL SERVICE KNOWSLEY Michele White Madeline Jones Elizabeth Gibbons.

Approach to medical liver biopsies Dr Behrang Mozayani Consultant Histopathologist Southmead hospital Bristol.

 Fatty liver disease can range from fatty liver alone (steatosis) to fatty liver associated with inflammation (steatohepatitis). This condition can occur.

Metabolic Factors / NAFLD on the Natural History of Chronic Hepatitis B or C in Asia Pei-Jer Chen National Taiwan University & Hospital.

Deranged LFTs Pathways A H Mohsen Dr A H Mohsen MD (KCL), MRCP, DTM&H Consultant Gastroenterologist.

Dr Jonathan Stenner.

F ATTY L IVER Shahin Merat, M.D. Associate Professor of Medicine Digestive Disease Research Center, Tehran University of Medical Sciences, 8 th International.

Fatty Liver and Pregnancy Shahin Merat, M.D. Professor of Medicine Digestive Disease Research Institute Tehran University of Medical Sciences 1.

Impact of weight management in chronic HCV Egyptian patients on liver fibrosis. By: Dr. Osama A. Fekry Lecturer of CN at the AUC Head of clinical Nutrition.

THE PRESENCE OF HEPATIC STEATOSIS WHEN NO OTHER CAUSES FOR SECONDARY HEPATIC FAT ACCUMULATION NAFLD MAY PROGRESS TO CIRRHOSIS AND IS LIKELY AN IMPORTANT.

Cholestatic Liver Disease Primary Biliary Cirrhosis.

Cholestatic liver diseases:

LFT Ordering Behavior Payam Parvinchiha DSR 2. Guidelines No guidelines for ordering of LFT Should not be a screening test for liver disease population-based.

Non-alcoholic Fatty Liver Disease

Cirrhosis 18 November 2009 Thomas C Sodeman MD Associate Professor of Medicine Chief, Division of Gastroenterology.

Evaluating the Patient With Abnormal Liver Tests-2 פרופ ' צבי אקרמן מבית חולים הדסה הר הצופים.

The Use of Mortality Data to Improve Risk Assessment CTHOLUA Seminar February, 2011 Robert Stout, Ph.D., President and Director Clinical Reference Laboratory.

INCIDENTAL FINDINGS Joel Thompson, MSIII November 19, 2008.

Hepatocellular Carcinoma from the ACC to Med E Paul M. Johnson Department of Internal Medicine University of North Carolina Hospitals February 12, 2010.

BSG Pathology Section Liver Slide Seminar, Birmingham, March Clinical Summaries - Stefan Hübscher Prof. Stefan Hubscher Case 1 Male, age 52. Recent.

Evaluation of Abnormal Liver Function Tests Cengiz Pata Gastroenterology Department Yeditepe University.

What’s this?. It’s 96% water It has over 500 functions It’s the largest internal organ Without it, you’d die! Liver disease is the 5th biggest killer.

Nonalcoholic Fatty Liver Disease / Nonalcoholic Steatohepatitis 소화기내과 R3 신아리 1.

F. 정 회 훈 Am J Gastroenterol 2012;107:46-52 Risk of Hepatocellular Carcinoma in Diabetic Patients and Risk Reduction Associated With Anti-Diabetic Therapy:

ALCOHOLIC LIVER DISEASE. Alcohol is one of the most common causes of chronic liver disease worldwide,In the UK, a unit of alcohol contains 8 g of ethanol.

Section 1: Introduction Dr Somen Banerjee, Director of Public Health London Borough Tower Hamlets.

Diagnostic Pathway for Chronic Liver Disease

Asymptomatic abnormal LFTs…..again!

Upper Gastrointestinal Cancers Top ⑩ Tips

Missing Cirrhosis on CT Scan

Managing abnormal LFTs in Primary care

Asymptomatic Abnormal LFTs NHS Lothian guideline

Jane E Scullion Respiratory Nurse Consultant

Guidelines for the diagnosis and management of Nonalcoholic Fatty Liver Disease (NAFLD): Update in 2012 Sameh M Fakhry MD, Msc, PhD Consultant of Gastroenterology,

Metabolic Disorders Hemochromatosis

Underwriting Screening Liver Test Abnormalities:

Primary biliary cirrhosis, cirrhotic stage

Summary Report: Management of Hepatitis C in Prisons

Chapter 12 Liver Transplantation 1

Orthotopic liver transplant, recurrent non-alcoholic steatohepatitis

More Than Meets the Eye: Identifying Who Is at Risk for NASH

Figure 2 A stage-based approach to the treatment of NAFLD

Non-invasive diagnosis of non-alcoholic fatty liver disease

Figure 1 Proposed algorithm for the management

Primary biliary cirrhosis, AMA negative

Nottingham Digestive Diseases Biomedical Research Unit

Alcohol Related Liver Disease Pathway

NAFLD Paul Trembling Consultant Hepatologist

When the journey from obesity to cirrhosis takes an early start

Asymptomatic Abnormal LFTs NHS Lothian guideline

Alcohol Related Liver Disease Pathway

Melissa Herrin, Jan Tate ScD, MPH & Amy Justice, MD, PhD

Laurent Castera, Mireen Friedrich-Rust, Rohit Loomba Gastroenterology

The Nottingham liver disease stratification pathway

Presentation transcript:

Dealing with NASH “mildly abnormal LFTs”

Liver disease is a national epidemic

Contribution of alcoholic liver disease to overall liver deaths

and a local disaster

Liverpool S.Tyne Knowsley Blackpool Manchester Wirral Gateshead Sunderland Sefton Newcastle Heywood Hartlepool Halton Blackburn Bolton Salford Oldham The North of England cluster has higher rates of Thiamine prescribing than the other SHA clusters

Are LFTs a useful test ?

How are LFTs ranges decided ► LFT values a continuum ► Abnormal are the extreme 2.5% ends ► “Normal” is shifting  8% of Americans have high LFTs (Clark AJG 2003) ► “Normal” may not represent “healthy”

Normal LFTs ► High “normal” LFTs assoc. with increased liver mortality (Kim BMJ 2004) ► 20% of HCV will have “normal” ALT (Kelly MJA 2002) (Kelly MJA 2002) ► 58% abn LFTs never investigated in primary care (Sherwood BMJ 2001) ALT RR liver death MF <

How good are we at investigating abnormal LFTs ? ► Retrospective audit of primary care  Nottingham  Jan - Jun 1995 ► 342 consecutive abnormal LFTs ► 157 suitable for FU (not normalised, RIP or moved)  91 (58%)no further investigation  97 (62%) significant pathology

What are the commonest causes of LFT abnormalities

Causes of abnormal LFTs 42Alcoholic liver disease (23 with cirrhosis) 26Fatty liver / NASH (11 fibrotic on biopsy) 12PBC / AIH / PSC 6Haemochromatosis 2Hepatitis B 6Hepatitis C 3Common bile duct stones 1α1-antitrypsin deficiency 6Cryptogenic hepatitis (Sherwood BMJ 2001)

Basics of NASH ► NASH is common ► Most NASH is undetected  Untested  Normal LFTs ► NASH is “metabolic syndrome in the liver”  Associated with obesity / DM ► Most patients with NASH don’t die of liver disease

But ► Obesity / NASH potent cofactor for fibrosis ► NASH cirrhosis  Poor prognosis  High risk of HCC

Cumulative risk of HCC in 820,000 male veterans in hospital ’85-90 El-Serag 2004

Practical management ► Exclude other disease – aetiological screen  Diagnosis other than NASH  Other synergistic pathologies ► Assess severity ► Treat cofactors ► Weight and lifestyle management ► (Specific therapy)

Liver aetiological screen ► Hep B S-Ag ► Hep C antibodies ► Ferritin / Iron studies ► Autoantibodies ► Coeliac disease ► A1-AT ► Copper studies

Assessment of severity ► LFTs - virtually useless !!! ► FBC (platelets) ► US screen

Specific assessment ► Fibroscan ► Fibrotest ► Traffic lights ► Other indices

Southampton Traffic light test ► HA >30μg/l or P3NP >5.5μg/l+1 ► HA >75μg/l+2 ► Platelets <150+1 ► Score 0Green0% risk liver death 1Amber3% risk liver death 1Amber3% risk liver death 2+Red18% risk liver death 2+Red18% risk liver death

Management ► Refer if evidence of  Advanced fibrosis  Other disease ► Lifestyle advice  Weight  Diabetes  Alcohol ► Lipid R x ► Specific Rx

Thank you

► NASH is 2-3% of population. ► 10-30% of NASH has the potential of developing into cirrhosis within 10 years. ► The emergence of significant fibrotic disease in developing countries, even in patients of normal weight or who are underweight is particularly concerning. ► More HCC in patients with Childs A undiagnosed NASH.